EA
TBPH icon

Ellsworth Advisors’s Theravance Biopharma TBPH Stock Holding History

Ellsworth Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,332
Closed -$670K – 193
2025
Q4 		$670K Buy
+33,332
New +$553K 0.13% 131

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ellsworth Advisors's TBPH Position: Q1 2026 in Review

Ellsworth Advisors sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 33,332 shares — an estimated $670K sold.

Ellsworth Advisors first reported a position in TBPH in Q4 2025 and held it in 1 quarter. The position peaked at $670K in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Ellsworth Advisors reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • Ellsworth Advisors sold 33,332 Theravance Biopharma shares in Q1 2026, an estimated $670K.
  • Ellsworth Advisors first reported a position in Theravance Biopharma in Q4 2025 and held it in 1 quarter.
  • Ellsworth Advisors's Theravance Biopharma position peaked at $670K in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Ellsworth Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.